中美药企达全球合作 首付78亿

  • 信达生物,礼来制药,肿瘤免疫
  • 大公报/周琳

信达生物制药(苏州)有限公司与美国礼来制药集团12日达成全球开发合作协议,首期里程碑付款总金额超过10亿美元(约78亿港元),成为迄今为止中国新药国际合作项目的所涉金额最大的一桩。

不久前,中国药企恒瑞医药将自身的单抗药物有授许可给美国Incyte,获得最高7.95亿美元的收益,这被美国媒体评论称“中国新药卖出了一个全球价”。

如今,这一金额纪录再被刷新。此次合作涉及三个目前最有前景的新型双特异性肿瘤免疫治疗抗体,三个抗体均使用来自于信达生物自主研发的PD-1单抗。其中,信达生物将合作主导中国市场的开发、生产和销售,礼来将合作主导国外市场的开发、生产和销售。

研发生产销售全面合作

“我们相信肿瘤免疫治疗的组合疗法将有潜力改变癌症治疗的方式。”礼来肿瘤研究副总裁Greg Plowman说,“我们很高兴同信达生物拓展我们之间的合作,进一步为中国和全世界的癌症病人开发潜在治疗方法。

目前在生物制药领域,中国与海外企业的合作方式已经有产品转让的先例。但是在研发、生产与销售的全面合作还没有,这是这次合作的重要意义。”信达制药董事长俞德超表示。如在合作研发的方式上,双方将通过合作的管理委员会,对药物开发的方案、进展做决策。

双方战略联盟的建立和进一步拓展,是中国第一个本土企业与全球500强企业在高端生物药领域从研发、注册、生产到销售达成全面合作,开创了中国生物制药企业与国际合作的创新模式。

俞德超表示,信达生物的发展模式是通过自身的创新治疗药物,与全球性制药企业达成战略性合作,将国际合作的收入支持创新药物的进一步产业化。

目前,中国药企百济神州、恒瑞医药以及信达生物,都在自身商业模式的拓展上顺利前行,凸显中国本土新药研发创新已渐入佳境。

This link:http://www.chemcd.com/news/19052.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.